ow strength Atropine (0.01%) eyedrops for treatment of progressive myopia in children and young adults-A Randomised Controlled Trial

Dr Abraham Kurian0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Children or Young adults in the age group 5-15 years.
•2.Myopic refractive error of spherical equivalent > 1.00D as measured by cycloplegic refraction
•3.Astigmatism of <1.50D as measured by cycloplegic refraction
•4.Documented progression of myopia
•5.Ability to understand and follow the study instructions you receive and likely to be amenable for 1 year followup.
•6.Normal ocular health other than refractive error
•7.Normal Intraocular pressure ( <21 mm Hg)

•1.Known Allergy or hypersensitivity to Atropine, Cyclopentolate, Phenyl ephrine or Proparacaine
•2.Amblyopia in atleast one eye
•3.History of significant cardiac or respiratory illness
•4.Current enrolment in another investigational study or participation in such a study within 30 days of entry into this study
•5.No previous or current use of contact lenses or bifocals or progressive lenses or other forms of treatment (including Atropine in any strength) for myopia
•6.Patient has a condition or situation which in the investigators opinion, may put the patient at a significant risk, may confound the study results, or interfere with the participation in the study.

发起方